Eighty-two percent of patients hit a clinically meaningful response threshold in just 11 subjects, which is either a genuinely striking early signal or a sample size too small to anchor much confidence on, and TG Therapeutics is betting it is the former. The company’s Phase 1 data for subcutaneous BRIUMVI in AChR-antibody-positive myasthenia gravis showed a mean 4.6-point improvement in MG-ADL at Week 24, with a median time to that minimal clinically important difference of just 30 days. That early onset matters in MG, where patients are managing daily functional deficits, not a biomarker surrogate.
The more consequential move is the Phase 2 design itself. Rather than testing BRIUMVI head-to-head against the existing standard or as standalone induction, TG Therapeutics has built a sequential protocol: all 120 enrollees first receive a single induction cycle of efgartigimod, the FcRn inhibitor FDA-approved for generalized MG in adults who are AChR-antibody positive, consisting of four weekly infusions. Only those who respond, defined by at least a 2-point MG-ADL improvement, proceed to randomization between BRIUMVI and placebo for 24 weeks. The primary endpoint is time to clinical worsening, either a 2-point MG-ADL increase from that post-induction baseline or a myasthenic crisis requiring hospitalization. This enriched-responder design is methodologically shrewd: it removes non-responders before randomization, sharpening the signal, but it also means the trial is testing a specific combination strategy, not BRIUMVI’s standalone durability in a broader MG population.
The rationale rests on a real clinical problem. FcRn inhibitors like efgartigimod work quickly but require repeated cycles to sustain benefit, creating chronic treatment burden. B-cell depletion through CD20-targeted therapy like BRIUMVI depletes the cells producing pathogenic AChR antibodies, with the hypothesis that durable B-cell suppression can hold the response that efgartigimod initiates. The MG treatment landscape already includes multiple approved FcRn inhibitors and complement inhibitors, so TG Therapeutics is not entering empty space. The argument here is not novelty of mechanism but differentiated sequencing strategy, which is a harder case to make in a regulatory submission and a formulary negotiation.
The single number to track as this trial progresses is the proportion of efgartigimod responders who ultimately enroll into the randomized phase. If a large fraction of the 120 screened patients fail induction and never reach randomization, the trial’s effective sample shrinks and the strategy’s clinical viability faces an early stress test before a single BRIUMVI dose is assigned.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
